Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 8/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | CYP4Z1 | Q86W10 | 6/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11051725 | 0.83 | SLC9A1 (0.54) | SLC9A1KEAP1CYP4Z1POLBMAPK1 | |
| SCHEMBL17490282 | 0.79 | SLC9A1 (0.50) | SLC9A1KEAP1CYP4Z1POLBMAPK1 | |
| SCHEMBL15199802 | 0.79 | SLC9A1 (0.56) | SLC9A1KEAP1CYP4Z1POLBMAPK1 | |
| SCHEMBL4779214 | 0.76 | SLC9A1 (0.47) | SLC9A1KEAP1CYP4Z1POLBMAPK1 | |
| SCHEMBL18948924 | 0.74 | SLC9A1 (0.46) | SLC9A1KEAP1CYP4Z1POLBMAPK1 | |
| SCHEMBL3260305 | 0.73 | SLC9A1 (0.58) | SLC9A1KEAP1CYP4Z1POLBMAPK1 | |
| SCHEMBL170155 | 0.71 | SLC9A1 (1.00) | SLC9A1KEAP1CYP4Z1POLBMAPK1 | |
| SCHEMBL29720118 | 0.71 | SLC9A1 (1.00) | SLC9A1KEAP1CYP4Z1POLBMAPK1 | |
| SCHEMBL3107495 | 0.71 | SLC9A1 (0.56) | SLC9A1KEAP1CYP4Z1POLBMAPK1 | |
| SCHEMBL19781430 | 0.71 | HDAC3 (0.48) | POLBMAPK1ALDH1A1CYP1A2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11239498-B2 | Electrolytic solution and lithium-ion battery | CONTEMPORARY AMPEREX TECHNOLOGY CO., LIMITED (CN) | 2022-02-01 | — | — | US | disclosed |
| US-20220001191-A1 | SYSTEMS AND METHODS FOR MODULATED MULTI-SPECTRAL MAGNETIC STIMULATION | ROUND RIVER RESEARCH CORPORATION (US) | 2022-01-06 | — | — | US | disclosed |
| EP-3517746-B1 | PARTICULATE MEASUREMENT SYSTEM | AVL TEST SYSTEMS INC (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20190326637-A1 | ELECTROLYTIC SOLUTION AND LITHIUM-ION BATTERY | CONTEMPORARY AMPEREX TECHNOLOGY CO., LIMITED (CN) | 2019-10-24 | — | — | US | disclosed |
| US-8153150-B2 | Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances for treatment of vascular disorder | ABBOTT LABORATORIES (US) | 2012-04-10 | — | — | US | disclosed |
| WO-2009144175-A1 | PROCESS FOR PREPARING 3-INDOLYL FATTY ACID AMIDES WITH SATURATED, UNSATURATED OR HYDROXY FATTY ACIDS | Technische Universität Dresden (DE) | 2009-12-03 | — | — | WO | disclosed |
| US-7514448-B2 | Azaindoles useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-07 | — | — | US | disclosed |
| US-20090022774-A1 | Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances for treatment of vascular disorder | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090022774-A1 | Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances for treatment of vascular disorder | MMP17, PLAT, THPO | SLC9A1 1621/4885KEAP1 3911/4885CYP4Z1 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.